Diabetes Technology Society Report on the FDA Digital Health Software Precertification Program Meeting.


Journal

Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 6 11 2018
medline: 25 4 2020
entrez: 6 11 2018
Statut: ppublish

Résumé

Diabetes Technology Society (DTS) convened a meeting about the US Food and Drug Administration (FDA) Digital Health Software Precertification Program on August 28, 2018. Forty-eight attendees participated from clinical and academic endocrinology (both adult and pediatric), nursing, behavioral health, engineering, and law, as well as representatives of FDA, National Institutes of Health (NIH), National Telecommunications and Information Administration (NTIA), and industry. The meeting was intended to provide ideas to FDA about their plan to launch a Digital Health Software Precertification Program. Attendees discussed the four components of the plan: (1) excellence appraisal and certification, (2) review pathway determination, (3) streamlined premarket review process, and (4) real-world performance. The format included (1) introductory remarks, (2) a program overview presentation from FDA, (3) roundtable working sessions focused on each of the Software Precertification Program's four components, (4) presentations reflecting the discussions, (5) questions to and answers from FDA, and (6) concluding remarks. The meeting provided useful information to the diabetes technology community and thoughtful feedback to FDA.

Identifiants

pubmed: 30394807
doi: 10.1177/1932296818810436
pmc: PMC6313279
doi:

Types de publication

Congress Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

128-139

Subventions

Organisme : NIA NIH HHS
ID : P30 AG028740
Pays : United States

Auteurs

Fraya King (F)

1 Mills-Peninsula Medical Center, San Mateo, CA, USA.

David C Klonoff (DC)

1 Mills-Peninsula Medical Center, San Mateo, CA, USA.

David Ahn (D)

2 Mary & Dick Allen Diabetes Center at Hoag, Newport Beach, CA, USA.

Saleh Adi (S)

3 University of California, San Francisco, San Francisco, CA, USA.

Erika Gebel Berg (EG)

4 American Diabetes Association, Arlington, VA, USA.

Jiang Bian (J)

5 University of Florida, Gainesville, FL, USA.

Kong Chen (K)

6 National Institutes of Health, Bethesda, MD, USA.

Andjela Drincic (A)

7 University of Nebraska, Omaha, NE, USA.

Michael Heyl (M)

8 Hogan Lovells LLP, Washington, DC, USA.

Michelle Magee (M)

9 Georgetown University, Washington, DC, USA.

Shelagh Mulvaney (S)

10 Vanderbilt University, Nashville, TN, USA.

Yarmela Pavlovic (Y)

11 Hogan Lovells LLP, San Francisco, CA, USA.

Priya Prahalad (P)

12 Stanford University, Stanford, CA, USA.

Michael Ryan (M)

13 McDermott Will & Emery LLP, Washington, DC, USA.

Ashutosh Sabharwal (A)

14 Rice University, Houston, TX, USA.

Shahid Shah (S)

15 Netspective Communications, Washington, DC, USA.

Elias Spanakis (E)

16 University of Maryland, Baltimore, MD, USA.

Bradley Merrill Thompson (BM)

17 Epstein Becker Green, Washington, DC, USA.

Michael Thompson (M)

3 University of California, San Francisco, San Francisco, CA, USA.

Jing Wang (J)

18 UT Health San Antonio, San Antonio, TX, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH